Cited by 122Radiopharmaceutical Chemistry and ApplicationsRadioactivity and Radon MeasurementsEffects of Radiation Exposure

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

A bone marrow toxicity model for 223 Ra alpha-emitter radiopharmaceutical therapy

Open access

Hobbs, Robert F, Song, Hong, Watchman, Christopher J, Bolch, Wesley E, Aksnes, Anne-Kirsti, Ramdahl, Thomas, Flux, Glenn D, Sgouros, George·2012·Physics in Medicine and Biology

DOI 10.1088/0031-9155/57/10/3207PMC PMC3442928

Open this paper in CoChat — free account

Abstract

Ra-223, an α-particle emitting bone-seeking radionuclide, has recently been used in clinical trials for osseous metastases of prostate cancer. We investigated the relationship between absorbed fraction-based red marrow dosimetry and cell level-dosimetry using a model that accounts for the expected localization of this agent relative to marrow cavity architecture. We show that cell level-based dosimetry is essential to understanding potential marrow toxicity. The GEANT4 software package was used to create simple spheres representing marrow cavities. Ra-223 was positioned on the trabecular bone surface or in the endosteal layer and simulated for decay, along with the descendants. The interior of the sphere was divided into cell-size voxels and the energy was collected in each voxel and interpreted as dose cell histograms. The average absorbed dose values and absorbed fractions were also calculated in order to compare those results with previously published values. The absorbed dose was predominantly deposited near the trabecular surface. The dose cell histogram results were used to plot the percentage of cells that received a potentially toxic absorbed dose (2 or 4 Gy) as a function of the average absorbed dose over the marrow cavity. The results show (1) a heterogeneous distribution of cellular absorbed dose, strongly dependent on the position of the cell within the marrow cavity; and (2) that increasing the average marrow cavity absorbed dose, or equivalently, increasing the administered activity resulted in only a small increase in potential marrow toxicity (i.e. the number of cells receiving more than 4 or 2 Gy), for a range of average marrow cavity absorbed doses from 1 to 20 Gy. The results from the trabecular model differ markedly from a standard absorbed fraction method while presenting comparable average dose values. These suggest that increasing the amount of radioactivity may not substantially increase the risk of toxicity, a result unavailable to the absorbed fraction method of dose calculation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1088/0031-9155/57/10/3207

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Basic anatomical and physiological data for use in radiological protection: reference values
Valentin, J. (2002) · Annals of the ICRP · doi:10.1016/s0146-6453(03)00002-2 · Cited by 2,024
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature
Bolch, W. E., Eckerman, K. F., Sgouros, G., & Thomas, S. R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056036 · Cited by 913
Self-citation
A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology
Erlandsson, K., Buvat, I., Pretorius, P. H., Thomas, B. A., & Hutton, B. F. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/21/r119 · Cited by 731
MIRD primer for absorbed dose calculations
LOEVINGER, R., Budinger, T. F., & Watson, E. E. (1988) · Medical Entomology and Zoology · Cited by 552
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Self-citation
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
Nilsson, S. F., Franzén, L., Parker, C. C., Tyrrell, C., Blom, R., Tennvall, J., Lennernäs, B., Petersson, U., Johannessen, D. C., Sokal, M., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70147-x · Cited by 493
Radioimmunotherapy with alpha-emitting nuclides
McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., & Scheinberg, D. A. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050306 · Cited by 403
Self-citation
High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?
Bruland, Ø. S., Nilsson, S. F., Fisher, D. R., & Larsen, R. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0841 · Cited by 356
MIRD Primer for Absorbed Dose Calculations
Malamud, H. (1989) · Clinical Nuclear Medicine · doi:10.1097/00003072-198909000-00027 · Cited by 328

Show all 43 references

Research works printed but not linked: 10

Akabani G, 2003, J. Nucl. Med., 44, 792
Henriksen G, 2002, Cancer Res., 62, 3120
Henriksen G, 2003, J. Nucl. Med., 44, 252
2003, ICRP Publication, 89
Lewington V J, 2010, ASCO Genitourinary Cancers Symp.
Liepe K, 2009, Curr. Opin. Investig. Drugs, 10, 1346
Sgouros G, 1993, J. Nucl. Med., 34, 689
Shah A P, 2003, J. Nucl. Med., 44, 774
Stabin M G, 2005, J. Nucl. Med., 46, 1023
Watchman C J, 2005, J. Nucl. Med., 46, 1171

Sorted by citations

Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 1,032
Self-citation
A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?
de Kruijff, R. M., Wolterbeek, H. T., & Denkova, A. G. (2015) · Pharmaceuticals · doi:10.3390/ph8020321 · Cited by 254
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
Carrasquillo, J. A., O’Donoghue, J. A., Pandit-Taskar, N. D., Humm, J. L., Rathkopf, D. E., Slovin, S. F., Williamson, M. J., Lacuna, K. P., Aksnes, A.-K., Larson, S. M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2427-6 · Cited by 184
Self-citation
Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride
Pacilio, M., Ventroni, G., Vincentis, G. D., Cassano, B., Pellegrini, R., Castro, E. D., Frantellizzi, V., Follacchio, G. A., Garkavaya, T., Lorenzon, L., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3150-2 · Cited by 146
Dosimetry of 223Ra-chloride: dose to normal organs and tissues
Laßmann, M., & Noßke, D. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2265-y · Cited by 125
MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for Dosimetric Analysis of Biologic Response of Multicellular Populations
Vaziri, B., Wu, H., Dhawan, A. P., Du, P., & Howell, R. W. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131037 · Cited by 130
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223 Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
Chittenden, S. J., Hindorf, C., Parker, C. C., Lewington, V. J., Pratt, B. E., Johnson, B., & Flux, G. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157123 · Cited by 118
Self-citation
Radionuclides for Targeted Therapy: Physical Properties
Stokke, C., Kvassheim, M., & Blakkisrud, J. (2022) · Molecules · doi:10.3390/molecules27175429 · Cited by 112
Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis
Abou, D. S., Ulmert, D., Doucet, M., Hobbs, R. F., Riddle, R. C., & Thorek, D. L. J. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv380 · Cited by 102
Self-citation
Targeted Alpha Therapy: Current Clinical Applications
Liberal, F. D. C. G., O’Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3576 · Cited by 103
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95
Self-citation
Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: α Therapy with 223Ra-Dichloride
Pandit-Taskar, N. D., Larson, S. M., & Carrasquillo, J. A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112482 · Cited by 97
Current perspectives on bone metastases in castrate-resistant prostate cancer
Logothetis, C. J., Morris, M. J., Den, R. B., & Coleman, R. E. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9719-4 · Cited by 91
Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation
Malamas, A. S., Gameiro, S. R., Knudson, K. M., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.13520 · Cited by 91
The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer
Murray, I., Chittenden, S. J., Denis-Bacelar, A. M., Hindorf, C., Parker, C. C., Chua, S. C., & Flux, G. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3744-y · Cited by 78
Self-citation
Targeted and Nontargeted α-Particle Therapies
McDevitt, M. R., Sgouros, G., & Sofou, S. (2018) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-120931 · Cited by 76
Self-citation
Dosimetry for Radiopharmaceutical Therapy
Sgouros, G., & Hobbs, R. F. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.03.007 · Cited by 74
Self-citation
Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153
Liberal, F. D. C. G., Tavares, A., & Tavares, J. M. R. S. (2016) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2016.01.003 · Cited by 65
A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry
Hobbs, R. F., Song, H., Huso, D. L., H Sundel, M., & Sgouros, G. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/13/4403 · Cited by 61
Self-citation
ICRU Report 98, Stochastic Nature of Radiation Interactions: Microdosimetry
Braby, L. A., Conte, V., Dingfelder, M., GOODHEAD, D. T., Pinsky, L. S., Rosenfeld, A. B., Sato, T., Waker, A. J., Guatelli, S., Magrin, G., et al. (2023) · Journal of the ICRU · doi:10.1177/14736691231211380 · Cited by 61
Radium-223 in the Treatment of Osteoblastic Metastases: A Critical Clinical Review
Humm, J. L., Sartor, O. A., Parker, C. C., Bruland, Ø. S., & Macklis, R. M. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.12.061 · Cited by 61
Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters
Sgouros, G. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.11.002 · Cited by 60
Self-citation
Internal microdosimetry of alpha-emitting radionuclides
HOFMANN, W., Li, W. B., Friedland, W., Miller, B. W., Madas, B. G., Bardiès, M., & Balásházy, I. (2019) · Radiation and Environmental Biophysics · doi:10.1007/s00411-019-00826-w · Cited by 59
Targeted α-Particle Therapy of Bone Metastases in Prostate Cancer
Jadvar, H., & Quinn, D. I. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000290 · Cited by 52
Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed
Tronchin, S., Forster, J. C., Hickson, K., & Bezak, E. (2022) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ac5fe0 · Cited by 55
Redefining Relative Biological Effectiveness in the Context of the EQDX Formalism: Implications for Alpha-Particle Emitter Therapy
Hobbs, R. F., Howell, R. W., Hong, S., Baechler, S., & Sgouros, G. (2014) · Radiation Research · doi:10.1667/rr13483.1 · Cited by 48
Self-citation
MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling
Katugampola, S., Wang, J., Rosen, A., & Howell, R. W. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263253 · Cited by 45
A Radium-223 microgenerator from cyclotron-produced trace Actinium-227
Abou, D. S., Pickett, J., Mattson, J. E., & Thorek, D. L. J. (2016) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2016.10.015 · Cited by 44
Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with223Ra: The Role of Bystander Effects and Their Potential for Therapy
Leung, C. N., Canter, B. S., Rajon, D. A., Bäck, T. A., Fritton, J. C., Azzam, E. I., & Howell, R. W. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227835 · Cited by 44
Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow
Tranel, J., Feng, F. Y.-C., James, S. S., & Hope, T. A. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/abd3ef · Cited by 40
Improving the dose–myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP
Pacilio, M., Ventroni, G., Basile, C., Ialongo, P., Becci, D., & Mango, L. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2552-2 · Cited by 34
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Hasan, H., Deek, M. P., Phillips, R., Hobbs, R. F., Malek, R. A., Radwan, N., Kiess, A. P., Dipasquale, S., Huang, J. G., Caldwell, T. G., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07000-2 · Cited by 31
Self-citation
Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box
Sgouros, G., Frey, E. C., Du, Y., Hobbs, R. F., & Bolch, W. E. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05583-x · Cited by 30
Self-citation
Systemic Radiotherapy of Bone Metastases With Radionuclides
Murray, I., & Du, Y. (2021) · Clinical Oncology · doi:10.1016/j.clon.2020.11.028 · Cited by 33
Rethinking Dosimetry: A European Perspective
Tran‐Gia, J., Cicone, F., Koole, M. J. B., Giammarile, F., Gear, J. I., Deshayes, E., Gabiña, P. M., Cremonesi, M., Wadsley, J., Bernhardt, P., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269378 · Cited by 26
Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods
Liberal, F. D. C. G., Tavares, A., & Tavares, J. M. R. S. (2014) · Medical Physics · doi:10.1118/1.4897240 · Cited by 26
Compartmental Model for 223Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate Cancer
Taprogge, J., Murray, I., Gear, J. I., Chittenden, S. J., Parker, C. C., & Flux, G. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.07.022 · Cited by 26
Self-citation
Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma
Cortez, A. G., Josefsson, A., McCarty, G. W., Shtekler, A., Rao, A., Austin, Z., & Nedrow, J. R. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.07.006 · Cited by 26
Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why
Gallicchio, R., Mastrangelo, P., Nardelli, A., Mainenti, P. P., Colasurdo, A. P., Landriscina, M., Guglielmi, G., & Storto, G. (2019) · Tumori Journal · doi:10.1177/0300891619851376 · Cited by 24
Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides
Li, W. B., Bouvier‐Capely, C., Vargas, C. S., Andersson, M., & Madas, B. G. (2022) · Radiation and Environmental Biophysics · doi:10.1007/s00411-022-01000-5 · Cited by 26
From palliative therapy to prolongation of survival: 223 RaCl 2 in the treatment of bone metastases
Liepe, K., & Shinto, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016640494 · Cited by 23
Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation
Nguyen, N. C., Shah, M. A., Appleman, L. J., Parikh, R. A., & Mountz, J. M. (2016) · International Journal of Molecular Imaging · doi:10.1155/2016/2568031 · Cited by 24
Uptake of Radium-223 Dichloride and Early [18F]NaF PET Response Are Driven by Baseline [18F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients
Letellier, A., Johnson, A. C., Kit, N. H., Savigny, J.-F., Batalla, A., Parienti, J., & Aide, N. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1132-4 · Cited by 23
Multi-Functionality in Theranostic Nanoparticles: is more Always Better?
Vatansever, F. (2012) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000e120 · Cited by 22
223Ra and other bone-targeting radiopharmaceuticals—the translation of radiation biology into clinical practice
Turner, P. G., & O’Sullivan, J. M. (2015) · British Journal of Radiology · doi:10.1259/bjr.20140752 · Cited by 22
Bone-targeted agents in the treatment of lung cancer
Silva, S. C., Wilson, C., & Woll, P. J. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015582178 · Cited by 19
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer
Benabdallah, N., Lu, P., Abou, D. S., Zhang, H., Ulmert, D., Hobbs, R. F., Gay, H. A., Simons, B. W., Saeed, M. A., Rogers, B. E., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266571 · Cited by 19
Self-citation
Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy
Yoshimoto, M., Yoshii, Y., Matsumoto, H., Shinada, M., Takahashi, M., Igarashi, C., Hihara, F., Tachibana, T., Doi, A., Higashi, T., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101706 · Cited by 18
Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety
Nilsson, S. F. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1045874 · Cited by 17
Microdosimetry and nanodosimetry for internal emitters
Li, W. B., HOFMANN, W., & Friedland, W. (2018) · Radiation Measurements · doi:10.1016/j.radmeas.2018.05.013 · Cited by 21
210Po poisoning as possible cause of death: forensic investigations and toxicological analysis of the remains of Yasser Arafat
Froidevaux, P., Bochud, F. O., Baechler, S., Castella, V., Augsburger, M. P., Bailat, C. J., Michaud, K., Straub, M., Pecchia, M., Jenk, T. M., et al. (2015) · Forensic Science International · doi:10.1016/j.forsciint.2015.09.019 · Cited by 16
The Role of Preclinical Models in Radiopharmaceutical Therapy
Sgouros, G., Hobbs, R. F., & Abou, D. S. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e121 · Cited by 16
Self-citation
Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225
Castillo, D., Saint‐Hubert, M. D., Crabbé, M., Struelens, L., & Koole, M. J. B. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03266-5 · Cited by 15
Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases
Racaru, L. V., Sinigaglia, M., Kanoun, S., Bouallègue, F. B., Tal, I., Brillouet, S., Bauriaud, M., Zerdoud, S., Dierickx, L., Vallot, D., et al. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000850 · Cited by 15
Acute Myeloid Leukemia After Radium-223 Therapy: Case Report
Varkaris, A. S., Gunturu, K. S., Kewalramani, T., & Tretter, C. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.11.002 · Cited by 14
Stochastic simulation of radium-223 dichloride therapy at the sub-cellular level
Gholami, Y. H., Zhu, X., Fulton, R., Meikle, S. R., Fakhri, G. E., & Kuncic, Z. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/15/6087 · Cited by 14
Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients
Fiz, F., Sahbai, S., Campi, C., Weissinger, M., Dittmann, H., Marini, C., Piana, M., Sambuceti, G., & la Fougère, C. J. (2017) · BioMed Research International · doi:10.1155/2017/3905216 · Cited by 13
Targeted Radiopharmaceutical Therapy for Bone Metastases
Mahajan, S., Gavane, S. C., & Pandit-Taskar, N. D. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.05.006 · Cited by 14
TOPAS a tool to evaluate the impact of cell geometry and radionuclide on alpha particle therapy
Liberal, F. D. C. G., McMahon, S. J., & Prise, K. M. (2021) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/abf29f · Cited by 14
Monte Carlo simulation of age-dependent radiation dose from alpha- and beta-emitting radionuclides to critical trabecular bone and bone marrow targets
Dant, J. T., Richardson, R. B., & Nie, L. H. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/10/3301 · Cited by 12
A cell-based dosimetry model for radium-223 dichloride therapy using bone micro-CT images and GATE simulations
Pinto, G. M., Bonifácio, D. A. B., de Sá, L. V., Lima, L. F. C., Vieira, I. F., & Lopes, R. T. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab6b42 · Cited by 12
Radiopharmaceuticals for Bone Metastases
Smith, A. W., Greenberger, B. A., Den, R. B., & Stock, R. G. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.005 · Cited by 11
Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with radium-223
Rajon, D. A., Canter, B. S., Leung, C. N., Bäck, T. A., Fritton, J. C., Azzam, E. I., & Howell, R. W. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1951392 · Cited by 11
Mechanistic Modeling of Radium-223 Treatment of Bone Metastases
Moreira, H., Liberal, F. D. C. G., O’Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.12.015 · Cited by 11
No evidence of association between psychological distress and pain relief in patients with bone metastases from castration‐resistant prostate cancer treated with 223Radium
Vincentis, G. D., Frantellizzi, V., Follacchio, G. A., Farcomeni, A., Pani, A., Samaritani, R., Schinzari, G., Santini, D., & Cortesi, E. (2019) · European Journal of Cancer Care · doi:10.1111/ecc.13112 · Cited by 10
Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients
Fosbøl, M. Ø., Petersen, R. H., Daugaard, G., Holm, S., Kjær, A., & Mortensen, J. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1212-1 · Cited by 9
Radiation Dosimetry in Theranostics: A Review
ZANZONICO, P. B. (2025) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.270852 · Cited by 8
Applying radiobiology to clinical molecular radiotherapy
Murray, I., & Flux, G. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.05.005 · Cited by 8
Self-citation
Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy
Bastiani, I., McMahon, S. J., Turner, P. G., Redmond, K. M., McGarry, C. K., Cole, A., O’Sullivan, J. M., Prise, K. M., Ainsbury, E. A., & Anderson, R. M. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.12.002 · Cited by 7
Embracing the Future of Clinical Trials in Radiation Therapy: An NRG Oncology CIRO Technology Retreat Whitepaper on Pioneering Technologies and AI-Driven Solutions
Xiao, Y., Benedict, S., Cui, Y., Glide‐Hurst, C. K., Graves, S. A., Jia, X., Kry, S. F., Li, H., Lin, L., Matuszak, M. M., et al. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.01.006 · Cited by 7
Self-citation
Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy
O’Neill, E. S., & Cornelissen, B. T. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.02.004 · Cited by 7
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Donners, R., Tunariu, N., Tovey, H., Hall, E., Chua, S. C., Cook, G., Du, Y., Blackledge, M., Parker, C. C., & Koh, D. (2023) · European Radiology · doi:10.1007/s00330-023-10172-7 · Cited by 8
Targeted Radionuclide Therapy
Jurcic, J. G., Wong, J. Y. C., Knox, S. J., Wahl, D. R., Rosenblat, T. L., & Meredith, R. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00022-8 · Cited by 7
Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
Mangano, A. M., Pacilio, M., Ialongo, P., Semprebene, A., Ventroni, G., & Mango, L. (2018) · Diagnostics · doi:10.3390/diagnostics8010018 · Cited by 7
Blind Image Restoration Enhances Digital Autoradiographic Imaging of Radiopharmaceutical Tissue Distribution
Lu, P., Nadia, B., Wen, J., Simons, B. W., Hanwen, Z., Hobbs, R. F., David, U., Baumann, B. C., Pachynski, R. K., Jha, A. K., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262270 · Cited by 6
Self-citation
Therapeutic efficacy of heterogeneously distributed radiolabelled peptides: Influence of radionuclide choice
Tamborino, G., Nonnekens, J., Struelens, L., Saint‐Hubert, M. D., Verburg, F. A., & Konijnenberg, M. (2022) · Physica Medica · doi:10.1016/j.ejmp.2022.02.021 · Cited by 6
Absorbed fractions for alpha particles in ellipsoidal volumes
Amato, E., Italiano, A., & Baldari, S. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/16/5449 · Cited by 8
IAEA Support to Medical Physics in Nuclear Medicine
Meghzifene, A., & Sgouros, G. (2013) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.11.008 · Cited by 6
Self-citation
Depth‐dependent concentrations of hematopoietic stem cells in the adult skeleton: Implications for active marrow dosimetry
Geyer, A. M., Schwarz, B. C., O’Reilly, S. E., Hobbs, R. F., Sgouros, G., & Bolch, W. E. (2016) · Medical Physics · doi:10.1002/mp.12056 · Cited by 6
Self-citation
Gravimetric Drop-on-Demand Inkjet Deposition for Imaging Phantoms with Traceable Activity
Jollota, S., Bergeron, D. E., Verkouteren, R. M., Nour, S., Fitzgerald, R., Kwon, O., Radtke, J. L., Bednarz, B. P., Miller, B. W., & DeWerd, L. A. (2024) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.111683 · Cited by 5
Monte Carlo Dose Estimation of Absorbed Dose to the Hematopoietic Stem Cell Layer of the Bone Marrow Assuming Nonuniform Distribution Around the Vascular Endothelium of the Bone Marrow: Simulation and Analysis Study
Kobayashi, N. (2025) · JMIRx Med · doi:10.2196/68029 · Cited by 5
EANM recommendations for dosimetry in targeted radionuclide therapy with alpha-emitters
Gabiña, P. M., Gleisner, K. S., Chouin, N., Tran‐Gia, J., Koole, M., Cremonesi, M., Denis-Bacelar, A. M., Cassano, B., Verburg, F. A., Brosch-Lenz, J., et al. (2026) · EANM Innovation · doi:10.1016/j.eanmi.2025.100018 · Cited by 6
Homomultimer Strategy for Improvement of Radiolabeled Peptides and Antibody Fragments in Tumor Targeting
Ebrahimi, F., & Hosseinimehr, S. J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220420131836 · Cited by 4
Radiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Danieli, R., Chiesa, C., & ZANZONICO, P. B. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_6 · Cited by 5
Aminopolycarboxylate Chelators Are Effective for Whole-body Clearance of Free 225ac: A Method to Reduce Unexpected Radiation Exposure During Targeted Alpha TherapyPreprint
Yoshimoto, M., Yoshii, Y., Matsumoto, H., Shinada, M., Takahashi, M., Igarashi, C., Hihara, F., Tachibana, T., Doi, A., Higashi, T., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-815298/v1 · Cited by 4
The role of radiotheranostics in personalized treatment for breast cancer
Sharma, D., Srivastava, S., Kagithala, N. R., Rahate, K., & Sridhar, S. B. (2025) · Medical Oncology · doi:10.1007/s12032-025-02825-y · Cited by 3
Human absorbed dose estimation for a new 175Yb-phosphonate based on rats data: Comparison with similar bone pain palliation agents
Vaez-Tehrani, M., Zolghadri, S., Yousefnia, H., & AFARIDEH, H. (2016) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2016.06.013 · Cited by 3
Radiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Chiesa, C., & ZANZONICO, P. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-26067-9_6-1 · Cited by 3
Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223.
Maruyama, K., Utsunomia, K., Nakamoto, T., Kawakita, S., Murota, T., & Tanigawa, N. (2018) · Europe PMC (PubMed Central) · doi:10.22038/aojnmb.2017.9896 · Cited by 3
Evaluation of the 223Ra-dichloride biodistribution models for the assessment of the doses from internal exposure
Водоватов, А. В., Чипига, Л. А., Petrova, A. E., & Stanzhevsky, A. A. (2020) · Pharmacy Formulas · doi:10.17816/phf20403 · Cited by 3
Radium-223 and concomitant therapies: prospects and prudence
Yeku, O., & Slovin, S. F. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.11.04 · Cited by 3
Treatment of skeletal metastases with 223Ra-chloride
Chalhoub, E., Chalouhy, C., & Sartor, O. A. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0103-5 · Cited by 2
Dosimetric Principles of Targeted Radiotherapy and Radioimmunotherapy
Vincentis, G. D., Frantellizzi, V., & Pacilio, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_15 · Cited by 2
S-values for radium-223 and absorbed doses estimates for 223RACL2 using three computational phantoms
Silva, C. C. O., da Silva, A. X., Braz, D., Lima, L. F. C., Segars, W. P., & de Sá, L. V. (2022) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2022.110387 · Cited by 2
RADIONUCLIDE THERAPY FOR BONE LESIONS IN CASTRATION-RESISTANT PROSTATE CANCER (STATE-OF-THE-ART LITERATURE REVIEW)
Solodiannikova, O., Шипко, А. Ф., Danilenko, V. V., & Sukach, G. (2022) · Проблеми радіаційної медицини та радіобіології = Problems of Radiation Medicine and Radiobiology · doi:10.33145/2304-8336-2022-27-131-137 · Cited by 2
An assessment of bone-seeking radionuclides for palliation of metastatic bone pain in a vertebral model
Sadremomtaz, A., & Masoumi, M. (2019) · Annals of Nuclear Medicine · doi:10.1007/s12149-019-01329-w · Cited by 2
Small-scale bone marrow dosimetry study for 225Ac
Tronchin, S., Forster, J. C., Hickson, K., & Bezak, E. (2025) · Physica Medica · doi:10.1016/j.ejmp.2025.104966 · Cited by 1
S-values for bone marrow dosimetry in preclinical radiopharmaceutical studies with rodents
Obaid, M., Rahmim, A., Segars, W. P., Brosch-Lenz, J., & Uribe, C. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00752-5 · Cited by 1
Radium-223 in Metastatic Castrate Resistant Prostate Cancer
Dan, T., Williams, N. L., & Den, R. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-31341-2_11 · Cited by 1
New Advances in Radioimmunotherapy for the Treatment of Cancers
Kraeber‐Bodéré, F., Bodet‐Milin, C., Rousseau, C., Carlier, T., Ferrer, L., Chouin, N., Haddad, F., Davodeau, F., Chatal, J., Faivre-Chauvet, A., et al. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_25 · Cited by 1

Authors: Hobbs, R. F., Song, H., Watchman, C. J., Bolch, W. E., Aksnes, A.-K., Ramdahl, T., Flux, G. D., & Sgouros, G.
Affiliations: Johns Hopkins University (US)
University of Arizona (US)
University of Florida (US)
Royal Marsden NHS Foundation Trust (GB)
Corresponding author: Hobbs, Robert F
Watchman, Christopher J
Bolch, Wesley E
Aksnes, Anne-Kirsti
Ramdahl, Thomas
Flux, Glenn D
Sgouros, George
ORCID: Hobbs, Robert F
Bolch, Wesley E
Flux, Glenn D
Venue: Physics in Medicine and Biology
Publisher: IOP Publishing
Published: 2012-05-01
Volume: 57
Issue: 10
Pages: 3207-3222
ISSN: 0031-9155 (ISSN-L)
1361-6560
DOI: 10.1088/0031-9155/57/10/3207
PMC: PMC3442928
OpenAlex: W2109768758
Cited by: 122
References: 43
Citations by year: 2026: 4 · 2025: 8 · 2024: 3 · 2023: 4 · 2022: 13 · 2021: 11 · 2020: 14 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 13 · 2015: 13 · 2014: 6 · 2013: 7 · 2012: 3
FWCI: 7.00
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Physics in Medicine and Biology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR000064)
National Cancer Institute (R01CA157542, R01CA116477)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
Keywords: radium-223, alpha-emitting radiopharmaceuticals, myelosuppression, fraction absorbed, trabecular bone, bone-seeking radionuclides, prostate cancer bone metastasis, absorbed dose distribution, Geant4 simulation
MeSH terms: Alpha Particles, Bone Marrow, Models, Biological, Radiation Dosage, Radium, Radiopharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A bone marrow toxicity model for 223 Ra alpha-emitter radiopharmaceutical therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks